LigaChem Biosciences, Inc.

CStone Advances CS5001 ROR1-ADC to Phase Ib Trial for First-line DLBCL Treatment

3 months ago

• CStone Pharmaceuticals has submitted a Phase Ib clinical trial application in Australia to evaluate CS5001 in combination with R-CHOP as first-line treatment for diffuse large B-cell lymphoma. • CS5001 has shown promising results in early trials, achieving 70% objective response rates in advanced B-cell lymphoma and 100% in Hodgkin lymphoma at the recommended Phase 2 dose. • The global multi-center trial will explore multiple treatment approaches, including CS5001 monotherapy and combination therapies for both lymphomas and solid tumors.

NextCure's LNCB74, a B7-H4 ADC, Enters Phase 1 Trial for Multiple Cancers

4 months ago

• NextCure has dosed the first patient in a Phase 1 study of LNCB74, an antibody-drug conjugate (ADC) targeting B7-H4, for various cancers. • The study aims to evaluate the safety, tolerability, and preliminary anti-tumor activity of LNCB74 in patients with multiple cancers. • LNCB74 received FDA clearance for its Investigational New Drug application in December 2024 and is being co-developed with LigaChem Biosciences. • NextCure is focused on developing innovative medicines for cancer patients who have not responded to or progressed on current therapies.